• Artelo Biosciences entered strategic collaboration with BioAI company ScienceMachine to accelerate development of its FABP5 inhibitor platform.
• ScienceMachine will apply its AI agent technology to analyze Artelo’s internal FABP datasets to identify new mechanisms, therapeutic opportunities, clinical biomarkers.
• Collaboration is using Phase 1 single ascending dose data from ART26.12-100 to flag proteins that may indicate FABP5 target engagement in ART26.12-treated healthy volunteers.
• Work since 2025 has generated preliminary multi-omic results in a psoriasis model slated for publication later this year.
• Partnership also identified protein and lipid signatures linked to ART26.12 dose-responsive analgesic effect to inform future studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280825PRIMZONEFULLFEED9707943) on April 28, 2026, and is solely responsible for the information contained therein.